PT2433637E - Utilização de derivados de quinazolina em doenças neurodegenerativas - Google Patents

Utilização de derivados de quinazolina em doenças neurodegenerativas Download PDF

Info

Publication number
PT2433637E
PT2433637E PT107323982T PT10732398T PT2433637E PT 2433637 E PT2433637 E PT 2433637E PT 107323982 T PT107323982 T PT 107323982T PT 10732398 T PT10732398 T PT 10732398T PT 2433637 E PT2433637 E PT 2433637E
Authority
PT
Portugal
Prior art keywords
neurodegenerative diseases
quinazoline derivatives
quinazoline
derivatives
neurodegenerative
Prior art date
Application number
PT107323982T
Other languages
English (en)
Inventor
Ana Martínez Gil
Carmen Gil Ayuso-Gontan
Concepción Pérez Martín
Ana Pérez Castillo
José Morales García
Miriam Redondo Sancho
Marina Sanz San Cristóbal
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of PT2433637E publication Critical patent/PT2433637E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT107323982T 2009-05-20 2010-05-20 Utilização de derivados de quinazolina em doenças neurodegenerativas PT2433637E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200930189A ES2353093B1 (es) 2009-05-20 2009-05-20 Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.

Publications (1)

Publication Number Publication Date
PT2433637E true PT2433637E (pt) 2014-09-09

Family

ID=42732572

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107323982T PT2433637E (pt) 2009-05-20 2010-05-20 Utilização de derivados de quinazolina em doenças neurodegenerativas

Country Status (10)

Country Link
US (1) US9192610B2 (pt)
EP (1) EP2433637B9 (pt)
JP (1) JP5563068B2 (pt)
AU (1) AU2010251044B2 (pt)
DK (1) DK2433637T5 (pt)
ES (2) ES2353093B1 (pt)
PL (1) PL2433637T3 (pt)
PT (1) PT2433637E (pt)
SI (1) SI2433637T1 (pt)
WO (1) WO2010133742A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2454966T3 (es) 2007-02-01 2014-04-14 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
NZ595747A (en) 2009-03-18 2015-06-26 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
ES2544519B1 (es) 2015-05-22 2016-03-04 Consejo Superior De Investigaciones Científicas (Csic) Quinazolinas S-sustituidas y sus aplicaciones terapéuticas para el tratamiento de enfermedades mediadas por PDE7
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP3359526A4 (en) 2015-10-05 2019-04-03 The Trustees of Columbia University in the City of New York ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
US20220315568A1 (en) * 2019-09-12 2022-10-06 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2005051974A2 (en) * 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
ES2308916B1 (es) * 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
BRPI0809244A2 (pt) 2007-03-27 2014-09-23 Omeros Corp Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7.
US20100179158A1 (en) * 2007-04-20 2010-07-15 Hoffman Charles S Inhibitors of cyclic amp phosphodiesterases

Also Published As

Publication number Publication date
AU2010251044A1 (en) 2012-03-01
ES2353093A1 (es) 2011-02-25
ES2353093B1 (es) 2012-01-03
SI2433637T1 (sl) 2014-09-30
EP2433637A1 (en) 2012-03-28
DK2433637T3 (en) 2014-08-18
JP2012527434A (ja) 2012-11-08
ES2498828T3 (es) 2014-09-25
US9192610B2 (en) 2015-11-24
WO2010133742A1 (es) 2010-11-25
PL2433637T3 (pl) 2014-12-31
EP2433637B9 (en) 2015-06-10
JP5563068B2 (ja) 2014-07-30
EP2433637B1 (en) 2014-06-11
US20120129877A1 (en) 2012-05-24
AU2010251044B2 (en) 2014-08-28
DK2433637T5 (da) 2015-08-31

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
IL219073A (en) A drug combination for cancer treatment
PT2433637E (pt) Utilização de derivados de quinazolina em doenças neurodegenerativas
IL221132A0 (en) Derivatives of betulin
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
SG10201507120TA (en) Treatment of diseases
EP2613786A4 (en) TREATMENT OF DISEASES
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
HRP20130538T1 (en) Therapeutic uses of quinazolinedione derivatives
HK1166472A1 (en) Treatment of dyskinesia related disorders
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2427183A4 (en) THERAPEUTIC COMPOUNDS
GB2468936B (en) Chlorination of sucrose-6-esters
EP2400848A4 (en) CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
IL219872A0 (en) Quinazoline derivatives
EP2496704A4 (en) THERAPEUTIC COMPOUNDS
GB201012926D0 (en) Compounds for treatment of inflammation
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2478359A4 (en) METHOD FOR IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS
HK1131039A1 (en) Pharmaceutical use of sophoricoside
EP2456309A4 (en) THERAPEUTIC COMPOUNDS
GB0906026D0 (en) Therapeutic compounds